Guess which drug is it?
Blackfynn announced that its is acquiring the rights to a candidate Parkinson’s disease treatment that others gave up on but is thought ready to move into pivotal Phase 3
Neither the investigative treatment nor the company that initially developed it — or other details of this acquisition — were identified in a Blackfynn press release.